Therapy Detail

Therapy Name CDX-3379 + Erlotinib
Therapy Description


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
CDX-3379 CDX3379|MEDI3379|KTN3379 HER3 (ERBB3) Antibody 13 CDX-3379 (KTN3379) is a monoclonal antibody that targets ERBB3 (HER3) and prevents ligand binding, which may reduce downstream signaling associated with ERBB2 (HER2) dimerization, and potentially leads to decreased cell proliferation and differentiation (NCI Drug Dictionary).
Erlotinib Tarceva CP358774 EGFR Inhibitor (Pan) 38 EGFR Inhibitor 1st gen 3 Tarceva (erlotinib) is a first-generation EGFR inhibitor, which is FDA approved for non-small cell lung carcinoma patients with EGFR exon 19 deletions and/or EGFR L858R and in combination with gemcitabine for patients with advanced pancreatic cancer (; PMID: 25302162).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT02014909 Phase I CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab Cetuximab + CDX-3379 CDX-3379 + Erlotinib A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Completed